Cagrilintide

FDA APPROVAL PENDING

Extensively Studied

Weight

Metabolic

Cagrilintide

Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes

Learn more

Weight

Cagrilintide

Metabolic

Amino acid sequence

38

Amino acids

4409da

Molecular weight

Peptide

Type

Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes. Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination.

Top researched benefits

Overview of Cagrilintide

Subcutaneous injection enables optimal bioavailability, targeting dual amylin and calcitonin receptors for satiety and metabolic regulation. Enhances insulin sensitivity and controls gastric emptying.

weight loss

  • Phase 3 trials demonstrate significant weight loss.
  • 22.7% weight loss with CagriSema combination, surpassing existing therapies.
  • 15.7% weight loss in diabetic patients with concurrent glycemic improvements.

metabolic

  • 2.2% HbA1c reduction with CagriSema versus semaglutide alone.
  • Amylin receptor activation enhances insulin sensitivity and glucose metabolism.

appetite control

  • Dual pathway satiety via amylin and calcitonin receptor activation.

Typical Dose

2.4mg weekly (after escalation)

Frequency

Once weekly, same day each week

Cycle Duration

Continuous long-term therapy

Storage

Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use within 30 days

Chemical Makeup

Key benefits

FDA development candidate with extensive Phase 3 data

Superior weight loss in combination with semaglutide (22.7%)

Once-weekly convenience

2.2% HbA1c reduction with CagriSema

Community interest

This peptide is still gaining traction in the community.

Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes

This overview is informational and based on aggregated descriptions from studies and user reports.

Was it helpful?Yes
No

Cagrilintide Molecular Information

View the scientifc details of Cagrilintide.

38

Amino Acids

Cagrilintide

?

?

Position 1

Lys

Lys

Position 2

Cys

Cys

Position 3

Asn

Asn

Position 4

Thr

Thr

Position 5

Ala

Ala

Position 6

Thr

Thr

Position 7

Cys

Cys

Position 8

Ala

Ala

Position 9

Thr

Thr

Position 10

Gln

Gln

Position 11

Arg

Arg

Position 12

Leu

Leu

Position 13

Ala

Ala

Position 14

Glu

Glu

Position 15

Phe

Phe

Position 16

Leu

Leu

Position 17

Arg

Arg

Position 18

His

His

Position 19

Ser

Ser

Position 20

Ser

Ser

Position 21

Asn

Asn

Position 22

Asn

Asn

Position 23

Phe

Phe

Position 24

Gly

Gly

Position 25

Pro

Pro

Position 26

Ile

Ile

Position 27

Leu

Leu

Position 28

Pro

Pro

Position 29

Pro

Pro

Position 30

Thr

Thr

Position 31

Asn

Asn

Position 32

Val

Val

Position 33

Gly

Gly

Position 34

Ser

Ser

Position 35

Asn

Asn

Position 36

Thr

Thr

Position 37

Pro

Pro

Position 38

Amino acid sequence
?Position 1
LysinePosition 2
CysteinePosition 3
AsparaginePosition 4
ThreoninePosition 5
AlaninePosition 6
ThreoninePosition 7
CysteinePosition 8
AlaninePosition 9
ThreoninePosition 10
GlutaminePosition 11
ArgininePosition 12
LeucinePosition 13
AlaninePosition 14
Glutamic acidPosition 15
PhenylalaninePosition 16
LeucinePosition 17
ArgininePosition 18
HistidinePosition 19
SerinePosition 20
SerinePosition 21
AsparaginePosition 22
AsparaginePosition 23
PhenylalaninePosition 24
GlycinePosition 25
ProlinePosition 26
IsoleucinePosition 27
LeucinePosition 28
ProlinePosition 29
ProlinePosition 30
ThreoninePosition 31
AsparaginePosition 32
ValinePosition 33
GlycinePosition 34
SerinePosition 35
AsparaginePosition 36
ThreoninePosition 37
ProlinePosition 38

Molecular Weight

4409Da

Chain Length

38Amino Acids

Type

Peptide

Cagrilintide Protocols

Subcutaneous injection to abdomen, thigh, or upper arm. Pre-filled pen design when commercially available.

GoalDosageFrequencyRoute
Weight Loss (Monotherapy)2.41 week rangeSubQ
Weight Loss (CagriSema)2.41 week rangeSubQ
Type 2 Diabetes Management2.41 week rangeSubQ with metformin
Dose Escalation Protocol0.2516 week rangeSubQ

Reconstitution Instructions

Materials needed:

Bacteriostatic water (standard BAC water acceptable for <30 days)Optional: 0.6% acetic acid to adjust pH to ~4.0Insulin syringesAlcohol swabs

Steps to reconstitute

  1. CRITICAL: Requires acidic pH (3.5-4.5) to prevent fibril formation
  2. Reconstitute slowly down vial side; swirl gently (do not shake)
  3. Verify pH 3.5-4.5 after reconstitution
  4. Solution must be clear—discard if cloudy or particulate
  5. Store refrigerated (2-8°C); inspect before each injection
  6. Allow 15-30 minutes to reach room temperature before injection
  7. Rotate injection sites weekly

Cagrilintide Cycle

The Cagrilintide Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.

Taking breaks between cycles may help maintain effectiveness and support better overall results.

Week 1-2
Gastrointestinal adaptation; mild nausea possible during dose escalation
Week 4-8
Early weight loss (2-5%); noticeable appetite reduction
Week 12-26
Significant weight loss acceleration (10-15%); improved satiety signals
Week 0-0
Peak efficacy (15-23% weight loss); sustained maintenance with continued therapy

Dosing tools

Cagrilintide Peptide Dosage Calculator

Calculate peptide doses with our visual syringe guide.

mg

Enter the total amount of peptide in the vial in milligrams (as stated on the label).

The dose you want to inject per administration, in mcg or mg.

1,000 mcg = 1 mg

1 mL

2 mL

3 mL

5 mL

Custom

Volume of bacteriostatic water you add to reconstitute the powder. Use BAC water for preservation.

Injection Results

Based on your vial and dilution inputs.

Cagrilintide

SINGLE COMPOUND

Volume per injection

0.05

mL

Concentration

10.00

mg/mL

Doses per vial

20

doses

Total injections per vial

20 injections

How it works

Based on a 10 mg Cagrilintide vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.

1mL / 100 units

5 units

0.050 mL

Reference Guide

Dosing Cycle

Peptide
Cagrilintide
Dosing
2.4mg weekly (after escalation)
Dosing Frequency
Once weekly, same day each week
Cycle Duration
Continuous long-term therapy
Storage
Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use within 30 days

Note: Triple agonist; microdose for fewer side effects

Reconstitution Tips

  • Use bacteriostatic water (BAC)contains 0.9% benzyl alcohol for preservation
  • Inject water slowlyaim down the vial wall, not directly onto powder
  • Never shakegently swirl or roll the vial until dissolved
  • Store properlyrefrigerate at 2-8°C after reconstitution
  • Use within 28 daysmost reconstituted peptides remain stable for about 4 weeks
  • Keep sterilealways clean vial tops with alcohol before drawing

Peptide Interactions

Research suggestions of Cagrilintide interactions with other common peptides and substances.

Weight

ret

Metabolic

Retatrutide

MONITOR

Compounded GI side effects create substantial risk without specialist supervision.

MONITOR

Weight

sem

Metabolic

Semaglutide

SYNERGISTIC

CagriSema combination achieves enhanced weight loss through complementary GLP-1 and amylin pathways.

SYNERGISTIC

Side effects

Monitor: Be careful when combining Cagrilintide with Retatrutide.

Contraindications

Not recommended in pregnancy or breastfeeding

Not yet commercially available (FDA approval expected Q1 2026)

Stop signs

Severe persistent nausea/vomiting preventing hydration

Pancreatitis signs (severe abdominal pain radiating to back)

Severe allergic reactions or anaphylaxis

Significant injection site reactions or abscess formation

Bad signs

Fibril formation at improper pH—solution must remain clearAggregation or precipitation indicates degradation
Was it helpful?Yes
No

Comments

0.0

0 reviews

5

4

3

2

1

No comments yet

Be the first to share your experience. Your review helps others make more informed decisions.

Frequently asked questions

What is a peptide dosage calculator?

A peptide dosage calculator is a free tool that converts your vial size, bacteriostatic water volume, and target dose into an exact syringe draw volume. Instead of doing the reconstitution math by hand, you enter three inputs and instantly get the concentration of your solution and how many milliliters or syringeunits to draw. This calculator works for single peptide compounds and multi-peptide blends.

How do I calculate peptide dosage from a vial?

To calculate your peptide dose, divide the total peptide content of your vial in micrograms by the volume of bacteriostatic water you added in milliliters. This gives you your solution concentration in mcg/mL. Then divide your target dose by that concentration to get your draw volume. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water gives a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1mL. This calculator automates all of those steps instantly.

How much Bacteriostatic water should I add to a peptide vial?

Most people add 2mL to 3mL of bacteriostatic water per vial, but the right amount depends on the dose you want to draw and the syringe size you are using. Adding 1mL to a 5mg vial gives you a concentration of 5,000 mcg/mL, making each dose very small in volume. Adding 2mL gives you 2,500 mcg/mL, which is easier to measure on a standard insulin syringe. A general guideline is to choose a volume that puts your typical dose somewhere between 10 and 30 units on a U-100 syringe. Use the calculator above to test different water volumes and find what works for your dose.

How are peptides different from proteins?

Both are made of amino acids, but peptides are much smaller than proteins. Because of their tiny size, peptides can act like tiny messengers in the body, sending specific signals to your cells to tell them exactly what to do.​

CagrilintideResearch References

Cagrilintide is an extensively studied compound

3Research references

Cagrilintide

Cagrilintide is an extensively studied compound

REDEFINE 1 Trial - Phase 3 Weight Loss

3,417 adults with obesity; 22.7% weight loss with CagriSema vs 2.4% placebo. New England Journal of Medicine.

2025

REDEFINE 2 Trial - Phase 3 Type 2 Diabetes

1,206 adults; 15.7% weight loss; 73.5% achieved HbA1c ≤6.5%. New England Journal of Medicine.

2025

Phase 2 Type 2 Diabetes Combination Study

32 weeks; 15.6% weight loss; 2.2% HbA1c reduction with CagriSema. The Lancet.

2023